HomeCompareTBPMF vs QYLD

TBPMF vs QYLD: Dividend Comparison 2026

TBPMF yields 222222.22% · QYLD yields 11.92%● Live data

vsPost on X →
After 10 years · $10,000 invested · DRIP enabled
🏆 TBPMF wins by $1.4076447531278624e+30M in total portfolio value
10 years
TBPMF
TBPMF
● Live price
222222.22%
Share price
$0.00
Annual div
$2.00
5Y div CAGR
0%
Payout ratio
50%
After 10 yrs · $10,000 · DRIP
Portfolio value
$1.4076447531278624e+30M
Annual income
$1,406,399,782,569,334,400,000,000,000,000,000,000.00
Full TBPMF calculator →
QYLD
Global X Nasdaq 100 Covered Call ETF
● Live price
11.92%
Share price
$17.15
Annual div
$2.04
5Y div CAGR
0%
Payout ratio
50%
After 10 yrs · $10,000 · DRIP
Portfolio value
$25.4K
Annual income
$5,659.31
Full QYLD calculator →

Portfolio growth — TBPMF vs QYLD

📍 TBPMF pulled ahead of the other in Year 1

Annual dividend income

🛡️

Recession Test — Did They Cut Dividends?

How each stock treated shareholders during the 3 biggest crises of the last 20 years

Crisis PeriodTBPMFQYLD
2008–2009
GFC
— No data— No data
2020 Q1–Q2
COVID
— No data— No data
2022 Q4
Rate Hike
— No data— No data
Based on dividend payment history. "Increased" = dividend grew during crisis. "Maintained" = held within 3%. "Cut" = reduced by more than 3%.
📅

Dividend Calendar Overlap

Combined, TBPMF + QYLD cover 0 of 12 monthsgood coverage

Jan
Feb
Mar
Apr
May
Jun
Jul
Aug
Sep
Oct
Nov
Dec
TBPMF pays
QYLD pays
Both pay
Neither
💰

Tax Bracket Optimizer

Which stock is actually better after tax? Adjust your rate to find out.

TBPMF
Annual income on $10K today (after 15% tax)
$18,888,888.89/yr
After 10yr DRIP, annual income (after tax)
$1,195,439,815,183,934,200,000,000,000,000,000,000.00/yr
QYLD
Annual income on $10K today (after 15% tax)
$1,013.51/yr
After 10yr DRIP, annual income (after tax)
$4,810.41/yr
At 15% tax rate, TBPMF beats the other by $1,195,439,815,183,934,200,000,000,000,000,000,000.00/year in after-tax income after 10 years on $10,000
⚖️

Lazy Portfolio Split Optimizer

What's the optimal mix of TBPMF + QYLD for your $10,000?

TBPMF: 50%QYLD: 50%
100% QYLD50/50100% TBPMF
Portfolio after 10yr
$7.038223765639312e+29M
Annual income
$703,199,891,284,667,200,000,000,000,000,000,000.00/yr
Blended yield
99.91%
🏛️

Copy Congress — What Are Politicians Buying?

Senate & House STOCK Act disclosures (last 90 days)

TBPMF buys
0
QYLD buys
1
PoliticianChamberTickerTypeAmountDate
Tim Moore🏢 House$QYLD▼ Sell$15,001 - $50,0002025-05-02
Tim Moore🏢 House$QYLD▲ Buy$15,001 - $50,0002025-04-07
Dwight Evans🏢 House$QYLD▼ Sell$1,001 - $15,0002022-11-14
Dwight Evans🏢 House$QYLD▼ Sell$1,001 - $15,0002020-10-29
STOCK Act mandates disclosure within 45 days of transaction. Data via FMP.Full tracker →
MetricTBPMFQYLD
Forward yield222222.22%11.92%
Annual dividend / share$2.00$2.04
Payout ratio50%50%
1-year div growth0%0%
5-year div CAGR0%0%
Portfolio after 10y$1.4076447531278624e+30M$25.4K
Annual income after 10y$1,406,399,782,569,334,400,000,000,000,000,000,000.00$5,659.31
Total dividends collected$1.4075632434891558e+30M$27.1K
Payment frequencyquarterlymonthly
SectorStockETF

Year-by-year: TBPMF vs QYLD ($10,000, DRIP)

YearTBPMF PortfolioTBPMF Income/yrQYLD PortfolioQYLD Income/yrGap
1← crossover$22,232,922$22,222,222.22$10,352$1,192.36+$22.22MTBPMF
2$46,198,082,523$46,174,293,296.41$10,830$1,347.57+$46198.07MTBPMF
3$89,718,752,943,223$89,669,320,994,923.30$11,460$1,539.07+$89718752.93MTBPMF
4$162,845,393,609,755,680$162,749,394,544,106,430.00$12,275$1,777.84+$162845393609.74MTBPMF
5$276,249,735,879,778,500,000$276,075,491,308,616,120,000.00$13,323$2,078.95+$276249735879778.50MTBPMF
6$437,989,462,258,048,500,000,000$437,693,875,040,657,100,000,000.00$14,667$2,463.34+$437989462258048512.00MTBPMF
7$649,026,142,700,674,900,000,000,000$648,557,493,976,058,700,000,000,000.00$16,396$2,960.57+$649026142700674875392.00MTBPMF
8$898,874,153,179,794,200,000,000,000,000$898,179,695,207,104,400,000,000,000,000.00$18,631$3,612.97+$8.988741531797941e+23MTBPMF
9$1,163,523,886,474,633,300,000,000,000,000,000$1,162,562,091,130,731,000,000,000,000,000,000.00$21,548$4,482.15+$1.1635238864746333e+27MTBPMF
10$1,407,644,753,127,862,300,000,000,000,000,000,000$1,406,399,782,569,334,400,000,000,000,000,000,000.00$25,398$5,659.31+$1.4076447531278624e+30MTBPMF

TBPMF vs QYLD: Complete Analysis 2026

TBPMFStock

Tetra Bio-Pharma Inc., a biopharmaceutical company, engages in the discovery and development of cannabinoid-derived drugs for inflammation, pain, ophthalmology, and oncology. The company develops PLENITUDE to treat cancer-related pain in advanced cancer patients; REBORN for the treatment of breakthrough cancer pain; Reduvo for chemotherapy-induced nausea and vomiting; ARDS-003 for the treatment of sepsis and prevention of acute respiratory distress syndrome; and SERENITY to treat cancer cachexia. It also develops PPP003 for painful dry eye and uveitis pain; and HCC011 for hepatocellular carcinoma. Tetra Bio-Pharma Inc. has an agreement with Cellvera Global Holdings LLC for the co-development of ARDS-003 as a combination product with Qifenda 400MG (Favipiravir), a commercial-stage broad-spectrum antiviral drug. The company is headquartered in Orléans, Canada.

Full TBPMF Calculator →

QYLDETF

The Global X Nasdaq 100 Covered Call ETF (QYLD) seeks to provide investment results that correspond generally to the price and yield performance, before fees and expenses, of the Cboe Nasdaq-100 BuyWrite V2 Index.

Full QYLD Calculator →
📬

Get this TBPMF vs QYLD comparison by email

Save your analysis + weekly dividend insights. Free forever.

More comparisons

TBPMF vs SCHDTBPMF vs JEPITBPMF vs OTBPMF vs KOTBPMF vs MAINTBPMF vs XYLDTBPMF vs JEPQTBPMF vs RYLD

⚠️ Educational purposes only. Not financial advice. Congressional trades sourced from SEC STOCK Act filings via FMP. Past performance does not guarantee future results.